Classic Kaposi Sarcoma in the United States over the last two decades: A clinicopathologic and molecular study of 438 non-HIV-related Kaposi Sarcoma patients with comparison to HIV-related Kaposi Sarcoma

2008 ◽  
Author(s):  
Kim M Hiatt ◽  
Ann M Nelson ◽  
Jack H Lichy ◽  
Julie C Fanburg-Smith
Keyword(s):  
United States ◽  
Kaposi Sarcoma ◽  
Molecular Study ◽  
The United States ◽  
Classic Kaposi Sarcoma

scholarly journals Risk of Kaposi sarcoma after solid organ transplantation in the United States

2018 ◽  
Vol 143 (11) ◽  
pp. 2741-2748 ◽  
Author(s):  
Elizabeth K. Cahoon ◽  
Martha S. Linet ◽  
Christina A. Clarke ◽  
Karen S. Pawlish ◽  
Eric A. Engels ◽  
...  
Keyword(s):  
United States ◽  
Organ Transplantation ◽  
Solid Organ Transplantation ◽  
Kaposi Sarcoma ◽  
The United States ◽  
Solid Organ

The Incidence of Kaposi Sarcoma Among Injection Drug Users With AIDS in the United States

2004 ◽  
Vol 37 (2) ◽  
pp. 1282-1287 ◽  
Author(s):  
Jonnae O Atkinson ◽  
Robert J Biggar ◽  
James J Goedert ◽  
Eric A Engels
Keyword(s):  
United States ◽  
Injection Drug Users ◽  
Drug Users ◽  
Kaposi Sarcoma ◽  
The United States ◽  
Injection Drug

scholarly journals AIDS-Related Kaposi Sarcoma, Version 2.2019

2019 ◽  
Vol 17 (2) ◽  
pp. 171-189 ◽  
Author(s):  
Erin Reid ◽  
Gita Suneja ◽  
Richard F. Ambinder ◽  
Kevin Ard ◽  
Robert Baiocchi ◽  
...  
Keyword(s):  
United States ◽  
Cervical Cancer ◽  
Clinical Practice ◽  
General Population ◽  
Kaposi Sarcoma ◽  
The United States ◽  
People Living With Hiv ◽  
Nodal Disease ◽  
Nccn Guidelines ◽  
Living With Hiv

As treatment of HIV has improved, people living with HIV (PLWH) have experienced a decreased risk of AIDS and AIDS-defining cancers (non-Hodgkin’s lymphoma, Kaposi sarcoma, and cervical cancer), but the risk of Kaposi sarcoma in PLWH is still elevated about 500-fold compared with the general population in the United States. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for AIDS-Related Kaposi Sarcoma provide diagnosis, treatment, and surveillance recommendations for PLWH who develop limited cutaneous Kaposi sarcoma and for those with advanced cutaneous, oral, visceral, or nodal disease.

scholarly journals Disparities in Kaposi sarcoma incidence and survival in the United States: 2000-2013

PLoS ONE ◽  
2017 ◽  
Vol 12 (8) ◽  
pp. e0182750 ◽  
Author(s):  
Kathryn E. Royse ◽  
Firas El Chaer ◽  
E. Susan Amirian ◽  
Christine Hartman ◽  
Susan E. Krown ◽  
...  
Keyword(s):  
United States ◽  
Kaposi Sarcoma ◽  
The United States

Detection of viral interleukin-6 in Kaposi sarcoma–associated herpesvirus–linked disorders

Blood ◽  
2001 ◽  
Vol 97 (7) ◽  
pp. 2173-2176 ◽  
Author(s):  
Yoshiyasu Aoki ◽  
Robert Yarchoan ◽  
Kathleen Wyvill ◽  
Shin-ichiro Okamoto ◽  
Richard F. Little ◽  
...  
Keyword(s):  
United States ◽  
Interleukin 6 ◽  
Blood Donors ◽  
Primary Effusion Lymphoma ◽  
Kaposi Sarcoma ◽  
The United States ◽  
Castleman Disease ◽  
Hiv Status ◽  
Hiv Patients ◽  
Multicentric Castleman Disease

Abstract Expression of a viral interleukin-6 (vIL-6) has been detected in certain Kaposi sarcoma (KS)–associated herpesvirus positive (KSHV+) lesions. The release of vIL-6 systemically and its contribution to the pathogenesis of HIV-related malignancies was studied. Serum vIL-6 was detected in 13 (38.2%) of 34 HIV+ patients with KS, in 6 (85.7%) of 7 HIV+patients with primary effusion lymphoma (PEL) and/or multicentric Castleman disease (MCD), and in 18 (60.0%) of 30 HIV+, mostly homosexual, individuals without KS, MCD, or PEL. By contrast, serum vIL-6 was detected in only 3 (23.1%) of 13 patients with classic KS, 1 (2.5%) of 40 blood donors from the United States, and 4 (19.0%) of 21 blood donors from Italy. Circulating vIL-6 levels were associated with HIV+ status (P < .0001). However, within the HIV+ cohort, serum vIL-6 levels were not associated with the occurrence of KSHV-associated malignancies (P = .43).

scholarly journals A case of classic Kaposi sarcoma in an immunocompetent human immunodeficiency virus–negative Dominican man

2020 ◽  
Vol 8 ◽  
pp. 2050313X2093824
Author(s):  
Kush Gupta ◽  
Aung Tun ◽  
Ashish Gupta ◽  
Leonard B Berkowitz ◽  
Raheel Anwar ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Soft Palate ◽  
Kaposi Sarcoma ◽  
The United States ◽  
Skin Lesions ◽  
Immunosuppressive Drug ◽  
Middle Aged ◽  
Mucosal Surfaces ◽  
Immunodeficiency Virus ◽  
Classic Kaposi Sarcoma

Kaposi sarcoma is an uncommon tumor that primarily arises in the skin and mucosal surfaces, but may metastasize to the internal organs. Four main variants of Kaposi sarcoma are recognized as the following: classic Kaposi sarcoma, which occurs in middle-aged or elderly men; epidemic Kaposi sarcoma, associated with human immunodeficiency virus infection; iatrogenic Kaposi sarcoma seen in patients on immunosuppressive drug therapy; and endemic Kaposi sarcoma. This report is of a case of classic Kaposi sarcoma in 55-year-old immunocompetent and human immunodeficiency virus–negative Dominican man who had lived in the United States for 2 years, who presented with a 2-year history of skin lesions on his lower extremities and soft palate. Biopsy of the soft palate was consistent with Kaposi sarcoma. The patient was treated with paclitaxel with a good response. This case report demonstrates the importance of recognizing that classic Kaposi sarcoma, first described almost 150 years ago, can still present in immunocompetent middle-aged men of all ethnicities.

Sign in / Sign up

Export Citation Format

Share Document